Navigation Links
Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
Date:1/9/2012

ROCKVILLE, Md., Jan. 9, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announces that President and CEO Richard Garr will present at the 2012 Biotech Showcase in San Francisco on Tuesday, January 10, 1:45-3:00pm PT. Garr will serve on the Therapeutic Focus Panel entitled, "Neurodegenerative Disease, Ophthalmology and Spinal Injury," featured in the Alliance for Regenerative Medicine (ARM) Insight Track. Garr will also present a business overview, including an update on the world's first FDA-approved stem cell injections in the cervical region, in its ongoing ALS cell therapy Phase I trial. He will also present an update on the recently FDA-approved advancement to Phase Ib dosing in depressed patients of its first-in-class NSI-189 small molecule drug, in its ongoing NSI-189/major depressive disorder (MDD) trial.

(Logo:  http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

The 2012 Biotech Showcase will be held at the Parc 55 Wyndham Hotel in San Francisco, January 9-11. For more information, see: http://www.ebdgroup.com/bts/index.php. Biotech Showcase runs concurrently to the world's largest annual healthcare investor conference, and provides private and public life science companies the opportunity to present to an audience of investors and business development executives interested in innovative biotech companies.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company has received approval from the FDA to conduct a Phase Ib safety trial evaluating NSI-189, its first small molecule compound, for the treatment of major depressive disorder (MDD).  Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.

For more information, please go to www.neuralstem.com.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2010 and the  quarterly report on Form 10-Q for the period ended September 30, 2011.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
3. Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference
4. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
5. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
6. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
7. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
8. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
9. Neuralstem Completes $5.25 Million Financing
10. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
11. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
Breaking Biology Technology:
(Date:6/9/2016)... 9, 2016 Paris Police ... video security solution to ensure the safety of people and ... during the major tournament Teleste, an international technology ... services, announced today that its video security solution will be ... back up public safety across the country. The system roll-out ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
Breaking Biology News(10 mins):